CTOs on the Move


 
Inizio is a strategic partner for health and life sciences with a full suite of medical, marketing, advisory and engagement services throughout the drug lifecycle.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

PvP Biologics

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion. Affecting an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Many patients continue to report persistent symptoms despite adhering to a gluten-free diet. The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. We have corporate offices in San Diego and research laboratories in Seattle.

Monticello Drug Companies

Monticello Drug Companies is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metro Vein Centers

Metro Vein Centers is a network of trusted vein specialists and vascular surgeons, specializing in varicose veins, spider veins and other venous conditions. Book your appointment online!

Monitored Therapeutics

Monitored Therapeutics Inc. is focused on solutions for the management of respiratory diseases like COPD, Asthma, Lung Transplant, and Cystic Fibrosis.

Spectrum Pharmaceuticals

Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.